anastrozole + zoledronic acid

Anastrozole + zoledronic acid is a combination therapy consisting of two pharmaceutical agents used primarily in the management of hormone receptor-positive breast cancer, particularly in postmenopausal women. Anastrozole is a non-steroidal aromatase inhibitor that reduces estrogen production by inhibiting the aromatase enzyme, thereby decreasing tumor growth driven by estrogen. Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to prevent bone loss and reduce skeletal-related events such as fractures. This combination is used to both treat breast cancer and mitigate the risk of osteoporosis or bone loss associated with aromatase inhibitor therapy[2][3][4].